FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116001192> ?p ?o ?g. }

• W2116001192 endingPage "7170s" @default.
• W2116001192 startingPage "7164s" @default.
• W2116001192 abstract "Myeloablative allogeneic stem cell transplantation (SCT) has been successful in the treatment of childhood acute myeloid leukemia (AML), but may be associated with significant toxicity and recurrent disease. Reduced-intensity allogeneic SCT may offer a less toxic approach to patients with AML. Targeted immunotherapy with gemtuzumab ozogamicin has been shown to be safe, well tolerated in children, and, as a single agent, gemtuzumab ozogamicin has induced responses in 30% of patients with recurrent CD33+ AML. There are no safety data with gemtuzumab ozogamicin post allogeneic SCT in children. Therefore, we explored the feasibility and toxicity of targeted immunotherapy following reduced-intensity allogeneic SCT in children with CD33+ AML.Eight patients with CD33+ AML received a reduced-intensity allogeneic SCT following fludarabine 30 mg/m2 for 6 days and busulfan 3.2 mg/kg (<4 years, 4 mg/kg/d) for 2 days. Donor sources included six 6/6 HLA-matched related peripheral blood stem cells, one 6/6 sibling cord blood, and one 4/6 unrelated cord blood.Day 30 and day 60 donor chimerisms in seven of eight evaluable patients were 96 +/- 2% (n = 7) and 94 +/- 3% (n = 6), respectively. Five of six patients (too early for one patient) received two doses of gemtuzumab ozogamicin and one patient received only one dose. After each dose, all patients developed grade 4 neutropenia, with recovery on median days 16 and 13, respectively, after dose 1 and dose 2. Grade 4 thrombocytopenia was only observed in 2 of 11 gemtuzumab ozogamicin courses. No patients have developed dose-limiting toxicity secondary to gemtuzumab ozogamicin.The administration of gemtuzumab ozogamicin post reduced-intensity allogeneic SCT in children with average risk AML is feasible and well tolerated with minimal toxicity. The maximal tolerated dose has yet to be determined for gemtuzumab ozogamicin post reduced-intensity allogeneic SCT in children with CD33+ AML. Additional studies in a larger group of patients will be required to adequately assess the safety of this approach." @default.
• W2116001192 created "2016-06-24" @default.
• W2116001192 creator A5001697191 @default.
• W2116001192 creator A5016047291 @default.
• W2116001192 creator A5019068922 @default.
• W2116001192 creator A5023129428 @default.
• W2116001192 creator A5033104475 @default.
• W2116001192 creator A5041488382 @default.
• W2116001192 creator A5043335221 @default.
• W2116001192 creator A5048733835 @default.
• W2116001192 creator A5049279048 @default.
• W2116001192 creator A5051652369 @default.
• W2116001192 creator A5056100797 @default.
• W2116001192 creator A5066133666 @default.
• W2116001192 creator A5068634507 @default.
• W2116001192 creator A5068912477 @default.
• W2116001192 creator A5075246827 @default.
• W2116001192 creator A5090974164 @default.
• W2116001192 date "2005-10-01" @default.
• W2116001192 modified "2023-10-17" @default.
• W2116001192 title "Preliminary Results of the Safety of Immunotherapy with Gemtuzumab Ozogamicin following Reduced Intensity Allogeneic Stem Cell Transplant in Children with CD33+ Acute Myeloid Leukemia" @default.
• W2116001192 cites W1274344746 @default.
• W2116001192 cites W1538198175 @default.
• W2116001192 cites W1702313568 @default.
• W2116001192 cites W1707184873 @default.
• W2116001192 cites W1842764967 @default.
• W2116001192 cites W1873141201 @default.
• W2116001192 cites W1933695467 @default.
• W2116001192 cites W1965979673 @default.
• W2116001192 cites W1972529152 @default.
• W2116001192 cites W1974082506 @default.
• W2116001192 cites W2004319386 @default.
• W2116001192 cites W2021977368 @default.
• W2116001192 cites W2053278212 @default.
• W2116001192 cites W2060336095 @default.
• W2116001192 cites W2062506977 @default.
• W2116001192 cites W2063940607 @default.
• W2116001192 cites W2067480394 @default.
• W2116001192 cites W2069199360 @default.
• W2116001192 cites W2096944251 @default.
• W2116001192 cites W2107943299 @default.
• W2116001192 cites W2136845772 @default.
• W2116001192 cites W2159289068 @default.
• W2116001192 cites W2180867777 @default.
• W2116001192 cites W2329587176 @default.
• W2116001192 cites W2334624221 @default.
• W2116001192 cites W2335612101 @default.
• W2116001192 cites W2340547456 @default.
• W2116001192 cites W2342320434 @default.
• W2116001192 cites W2400663726 @default.
• W2116001192 cites W2530924045 @default.
• W2116001192 cites W2581595210 @default.
• W2116001192 cites W2682204 @default.
• W2116001192 cites W3020917489 @default.
• W2116001192 cites W4240026283 @default.
• W2116001192 cites W4247185053 @default.
• W2116001192 cites W4247574810 @default.
• W2116001192 cites W4250981201 @default.
• W2116001192 cites W4251165644 @default.
• W2116001192 doi "https://doi.org/10.1158/1078-0432.ccr-1004-0018" @default.
• W2116001192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16203817" @default.
• W2116001192 hasPublicationYear "2005" @default.
• W2116001192 type Work @default.
• W2116001192 sameAs 2116001192 @default.
• W2116001192 citedByCount "44" @default.
• W2116001192 countsByYear W21160011922012 @default.
• W2116001192 countsByYear W21160011922013 @default.
• W2116001192 countsByYear W21160011922014 @default.
• W2116001192 countsByYear W21160011922015 @default.
• W2116001192 countsByYear W21160011922016 @default.
• W2116001192 countsByYear W21160011922017 @default.
• W2116001192 countsByYear W21160011922018 @default.
• W2116001192 countsByYear W21160011922021 @default.
• W2116001192 countsByYear W21160011922022 @default.
• W2116001192 crossrefType "journal-article" @default.
• W2116001192 hasAuthorship W2116001192A5001697191 @default.
• W2116001192 hasAuthorship W2116001192A5016047291 @default.
• W2116001192 hasAuthorship W2116001192A5019068922 @default.
• W2116001192 hasAuthorship W2116001192A5023129428 @default.
• W2116001192 hasAuthorship W2116001192A5033104475 @default.
• W2116001192 hasAuthorship W2116001192A5041488382 @default.
• W2116001192 hasAuthorship W2116001192A5043335221 @default.
• W2116001192 hasAuthorship W2116001192A5048733835 @default.
• W2116001192 hasAuthorship W2116001192A5049279048 @default.
• W2116001192 hasAuthorship W2116001192A5051652369 @default.
• W2116001192 hasAuthorship W2116001192A5056100797 @default.
• W2116001192 hasAuthorship W2116001192A5066133666 @default.
• W2116001192 hasAuthorship W2116001192A5068634507 @default.
• W2116001192 hasAuthorship W2116001192A5068912477 @default.
• W2116001192 hasAuthorship W2116001192A5075246827 @default.
• W2116001192 hasAuthorship W2116001192A5090974164 @default.
• W2116001192 hasConcept C10205521 @default.
• W2116001192 hasConcept C126322002 @default.
• W2116001192 hasConcept C141071460 @default.
• W2116001192 hasConcept C143998085 @default.
• W2116001192 hasConcept C176290653 @default.
• W2116001192 hasConcept C2776694085 @default.
• W2116001192 hasConcept C2776755627 @default.

• next